

## **Blood RNA and protein biomarkers are associated with vaping and dual use, and prospective health outcomes**

Andrew Gregory<sup>1</sup>, Zhonghui Xu<sup>1</sup>, Katherine Pratte<sup>2</sup>, Seth Berman<sup>1</sup>, Robin Lu<sup>1</sup>, Rahul Suryadevara<sup>1</sup>, Robert Chase<sup>1</sup>, Jeong H. Yun<sup>1,3</sup>, Aabida Saferali<sup>1</sup>, Craig P. Hersh<sup>1,3</sup>, Edwin K. Silverman<sup>1,3</sup>, Russell P. Bowler<sup>4</sup>, Laura E. Crotty Alexander<sup>5,6</sup>, Adel Boueiz<sup>1,3\*</sup>, Peter J. Castaldi<sup>1,7\*</sup>

<sup>1</sup>Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; <sup>2</sup>Department of Biostatistics, National Jewish Health, Denver, CO; <sup>3</sup>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; <sup>4</sup>Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO; <sup>5</sup>Division of Pulmonary, Critical Care, Physiology and Sleep Medicine, University of California San Diego (UCSD), La Jolla, CA; <sup>6</sup>Pulmonary Critical Care Section, Veterans Affairs (VA) San Diego Healthcare System, La Jolla, CA; <sup>7</sup>Division of General Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

\* Equal contribution

**Corresponding Author:** Peter J. Castaldi, MD, MSc, Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, Email: [repjc@channing.harvard.edu](mailto:repjc@channing.harvard.edu)

**Authors' email addresses:** Andrew Gregory ([andrew.gregory@channing.harvard.edu](mailto:andrew.gregory@channing.harvard.edu)), Zhonghui Xu ([zhonghui.xu@channing.harvard.edu](mailto:zhonghui.xu@channing.harvard.edu)), Katherine Pratte ([PratteK@njhealth.org](mailto:PratteK@njhealth.org)), Seth Berman ([seth.berman@channing.harvard.edu](mailto:seth.berman@channing.harvard.edu)), Robin Lu ([robin.lu@channing.harvard.edu](mailto:robin.lu@channing.harvard.edu)), Rahul Suryadevara ([rahul.suryadevara@channing.harvard.edu](mailto:rahul.suryadevara@channing.harvard.edu)), Robert Chase ([robert.chase@channing.harvard.edu](mailto:robert.chase@channing.harvard.edu)), Jeong H. Yun ([jeong.yun@channing.harvard.edu](mailto:jeong.yun@channing.harvard.edu)), Aabida Saferali ([aabida.saferali@channing.harvard.edu](mailto:aabida.saferali@channing.harvard.edu)), Craig P. Hersh ([craig.hersh@channing.harvard.edu](mailto:craig.hersh@channing.harvard.edu)), Edwin K. Silverman ([ed.silverman@channing.harvard.edu](mailto:ed.silverman@channing.harvard.edu)), Russell P. Bowler ([BowlerR@njhealth.org](mailto:BowlerR@njhealth.org)), Laura E. Crotty Alexander ([lca@ucsd.edu](mailto:lca@ucsd.edu)), Adel Boueiz ([adel.boueiz@channing.harvard.edu](mailto:adel.boueiz@channing.harvard.edu)), Peter J. Castaldi ([peter.castaldi@channing.harvard.edu](mailto:peter.castaldi@channing.harvard.edu))

#### **Author Contributions:**

Drs. Boueiz and Castaldi had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, had authority over manuscript preparation and the decision to submit the manuscript for publication.

*Study concept and design:* Gregory, Xu, Boueiz, Castaldi

*Acquisition, analysis, or interpretation of data:* All authors

*Drafting of the manuscript:* Gregory, Boueiz, Castaldi

*Critical revision of the manuscript for important intellectual content:* All authors

*Statistical analysis:* Gregory, Xu, Castaldi, Boueiz

*Obtained funding:* Boueiz, Castaldi, Silverman

*Study supervision:* All authors

All authors gave final approval of the version to be published.

**Keywords:** biomarkers, vaping, ENDS, e-cigarettes, smoking, genomics

## Abstract

**Background:** Electronic nicotine delivery systems (ENDS) are driving an epidemic of vaping. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking) will facilitate studies of the health effects of vaping. To identify putative biomarkers of vaping and dual use, we performed association analysis in an observational cohort of 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data and self-reported current vaping and smoking behavior.

**Methods:** Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes.

**Results:** We identified three transcriptomic and three proteomic associations with vaping, and 90 transcriptomic and 100 proteomic associations to dual use. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (three transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (two transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality, and respiratory exacerbations.

**Conclusions:** In summary, vaping and dual use are associated with RNA and protein blood-based biomarkers that are also associated with adverse health outcomes.

## 1 **Introduction**

2           The high prevalence of electronic cigarette use (vaping) among both adolescents[1] and  
3 adult cigarette users[2] is a major public health concern. Electronic cigarettes, also referred to as  
4 electronic nicotine delivery systems (ENDS), were initially marketed as a means of smoking  
5 reduction, with the hope that their effects on the health of cigarette users would be a net positive.  
6 However, vaping is associated with acute respiratory symptoms[3–5] and lung injury[6,7] and is  
7 likely to be associated with long-term adverse health effects. Vaping companies are targeting  
8 young people as a profitable demographic and promoting ENDS use beyond the population of  
9 established cigarette users, resulting in an ongoing epidemic of vaping in adolescents and non-  
10 cigarette user adults that is clearly detrimental to public health[8–10].

11           The Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and  
12 Drug Administration (FDA) regulatory oversight over tobacco products which, by the FDA  
13 Deeming Regulation of 2016, includes ENDS. Thus, the FDA is responsible for reviewing the  
14 safety of all ENDS products introduced to market after February 15, 2007. To facilitate this  
15 review process, it is important to determine whether there are validated biomarkers of ENDS use  
16 and combined use of ENDS and cigarettes (dual use). While biomarkers of vaping and dual use  
17 have been reported, few if any vaping biomarkers have been assessed for their association to  
18 prospective health outcomes, and the predictive performance of multi-biomarker panels has not  
19 been assessed. In this paper, the term biomarker refers to molecular measurements tested for  
20 association to vaping or smoking exposure, which we distinguish from validated biomarkers in  
21 which a specific association has been demonstrated in multiple studies. Validated biomarkers  
22 that are also predictive of prospective health events can be considered for use as surrogate  
23 outcomes in safety and health assessments[11,12] which would be a useful tool for evaluating

24 the health effects of an increasingly diverse array of ENDS products. Thus, the goal of this study  
25 is to establish a set of candidate biomarkers for future validation and further study as potential  
26 surrogate outcomes.

27 We hypothesized that vaping and dual use are associated to multi-omic biomarkers, and  
28 that a subset of these biomarkers would be associated with the development of pulmonary and  
29 cardiovascular disease. We conducted high throughput transcriptomic and proteomic analyses  
30 that identified over 100 biomarkers associated with vaping and dual use in a cohort of adult  
31 current and former cigarette users in the COPDGene study. We tested these biomarkers for  
32 association with prospective spirometric changes, mortality, and incident cardiovascular disease,  
33 identifying dozens of significantly associated biomarkers. We also investigated the extent to  
34 which multimarker panels can predict vaping and smoking status and the development of  
35 prospective health outcomes.

36

## 37 **Methods**

### 38 *Study description*

39 The COPDGene study recruited 10,198 non-Hispanic White and Black cigarette users  
40 with at least 10 pack-years of lifetime cigarette smoking history at 21 U.S. clinical centers  
41 (NCT00608764, [www.copdgene.org](http://www.copdgene.org))[13] between 2007 and 2011. COPDGene obtained five-  
42 year follow-up and is currently obtaining 10-year follow-up of available subjects to collect  
43 longitudinal data on study participants. A total of 6,756 subjects completed their five-year study  
44 visit (Visit 2) and the 10-year study visit (Visit 3) is ongoing at time of writing. Data collected  
45 includes questionnaires, spirometry, and self-reported smoking and vaping behaviors. At Visit 2,

46 whole-blood RNA sequencing (RNA-seq), plasma protein measurements (SOMAScan version  
47 4.0 (5.0K) assay for human plasma), and plasma cotinine were obtained from a subset of  
48 subjects. Throughout the study, subjects were also regularly contacted via the phone or Internet  
49 as part of the COPDGene Longitudinal Follow-up (LFU) program to assess interval events,  
50 including respiratory exacerbations, incident comorbidities, and mortality. Definitions of  
51 respiratory exacerbations, incident comorbidities, and mortality assessment are included in the  
52 supplementary materials of the online preprint. Written informed consents were obtained for all  
53 subjects, and each clinical site obtained institutional review board approval.

54

### 55 *Vaping and smoking groups*

56 Starting from Visit 2, vaping was determined by self-report including ever use, current  
57 use, intensity, cartridge size, brand, and flavoring. The four comparison groups for biomarker  
58 discovery (vapers, current cigarette users, former cigarette users, and dual users) were defined  
59 based on the subjects' questionnaire responses at Visit 2. Vapers were subjects who reported  
60 using at least one e-cigarette within the prior week and had a history of smoking tobacco  
61 cigarettes, but not within the last 30 days. Current cigarette users reported current smoking with  
62 an average of at least one cigarette per day without any e-cigarette use. Dual users were vapers  
63 who also reported current smoking, and former cigarette users were defined as those who  
64 reported a history of smoking but did not meet criteria for current smoking or vaping. In most of  
65 the reported analyses, former cigarette users are used as the reference group. Differences in  
66 baseline characteristics between groups were assessed with Kruskal-Wallis and chi-square tests  
67 for continuous and categorical measurements, respectively.

68

## 69 *RNA-sequencing*

70           The extraction protocol for total blood RNA was performed either manually or with the  
71 Qiagen QIAcube extraction robot according to the company's standard operating procedure.  
72 RNA samples with an RNA integrity number (RIN) > 6 and a concentration of  $\geq 25 \mu\text{g}/\mu\text{l}$  were  
73 sequenced. Library preparation was performed with the Illumina TruSeq Stranded Total RNA  
74 with Ribo-Zero Globin kit (Illumina, Inc., San Diego, CA). Samples were sequenced to an  
75 average depth of 20 million 75 base pairs (bp) paired end reads on Illumina HiSeq 2500  
76 sequencers. Samples were sequenced to an average depth of 20 million 75 base pairs (bp) paired  
77 end reads on Illumina HiSeq 2500 sequencers. Reads were aligned to the GRCh38 genome using  
78 the STAR (version 2.5.2b) align. Gene annotations and transcript GTF were downloaded from  
79 the Biomart Ensembl database (Ensembl Genes release 94, GRCh38.p12 assembly). Quality  
80 control was performed using the FastQC and RNA-SeQC programs, and samples were included  
81 for analysis if they met the following criteria: > 10 million total reads, > 80% of reads mapped to  
82 the reference genome, XIST and Y chromosome expression was consistent with reported sex, <  
83 10% of R1 reads in the sense orientation, Pearson correlation  $\geq 0.9$  with samples in the same  
84 library construction batch, and concordant genotype calls between variants called from RNA  
85 sequencing reads and DNA genotyping. Sequencing read counts were obtained from the  
86 featureCounts function in the Rsubread R package (v1.32.2). Genes were filtered to remove very  
87 low expressed genes; we limited our analysis to include only those genes which had an average  
88 counts per million (CPM) value > 1 in more than 20 subjects. The trimmed mean of M values  
89 (TMM) procedure from the edgeR R package (v3.24.3) was applied to account for the



90 differences in sequencing depth. The gene count data used for this analysis is available in GEO  
91 (accession number GSE158699). Counts were transformed to log<sub>2</sub> counts per million (CPM)  
92 values and quantile-normalized.

93

#### 94 ***Measurement of plasma protein biomarkers***

95 At Visit 2, plasma samples were assayed for 4,979 proteins in 5,670 COPDGene  
96 participants using the SOMAscan Human Plasma 5.0K assay, a multiplex aptamer-based assay  
97 (SomaLogic, Boulder, Colorado)[14]. The standardization process included within-plate  
98 hybridization, median signal normalization, and plate scaling and calibration of SOMAmers to  
99 control for inter-assay variation between analytes and batch differences between plates. Inverse  
100 normal transformation was applied to all protein measurements prior to association analysis.

101

#### 102 ***Cotinine measurements***

103 Plasma metabolite measurements were obtained from plasma for 1,136 subjects at  
104 COPDGene Visit 2 using the Metabolon Global Metabolomics Platform (Durham, NC,  
105 USA)[15]. Metabolite levels were quantified as raw area counts. Plasma cotinine levels were  
106 evaluated, and missing values were assigned a level of half the lowest detected amount of  
107 cotinine. Values were log-transformed, and differences in cotinine distribution between groups  
108 were evaluated with the Wilcoxon Rank Sum test. COPDGene metabolomic data are available in  
109 the [Metabolomics Workbench](https://www.metabolomicsworkbench.org/) of the NIH Common Fund's National Metabolomics Data  
110 Repository (Study ID ST001443;).

111

112 ***RNA-seq differential expression and protein association analyses***

113 We used the limma R package (v3.38.3)[16] to test for the associations between RNA  
114 transcripts and the vaping/smoking groups, using the former cigarette user group as the reference  
115 and adjusting for age, sex, race, and library preparation batch effects. The voom function was  
116 used in the RNA-seq analysis. Regression models for protein expression used identical  
117 covariates, with the exception that library preparation batch effects were replaced with a variable  
118 for clinical center. For both differential gene expression and protein association analyses, we  
119 corrected for multiple testing with the Benjamini-Hochberg method and applied a threshold of  
120 significance of a false discovery rate (FDR) of 10%[17]. For selected genes and proteins that  
121 were associated in only one contrast (vaping or dual only associations), we also conducted  
122 association analyses for the contrasts of vapers versus cigarette users, vapers versus dual users,  
123 and dual users versus cigarette users. Gene set enrichment analysis were performed using the fast  
124 gene set enrichment analysis (FGSEA) R package (v3.12)[18]. Further details are included in the  
125 supplementary materials of the online preprint.

126

127 ***Associations of transcripts and proteins to health outcomes***

128 Biomarkers significantly associated with vaping or dual use were tested for association to  
129 prospective health-related outcomes, namely change in FEV1 (absolute volume and percent  
130 change from baseline), prospective exacerbations, all-cause and respiratory mortality, and  
131 incident CVD. FEV<sub>1</sub> changes were computed by subtracting Visit 2 from Visit 3 FEV<sub>1</sub> values  
132 and dividing this difference by the number of years between both visits. FEV<sub>1</sub> changes were

133 calculated as both absolute and relative (as a percentage of the Visit 2 measurement) values. Data  
134 points >5 standard deviations from the mean were excluded from analysis.

135 The FEV1 outcomes were evaluated using multivariable linear regression models, and the  
136 time-to-event outcomes were evaluated using Cox-proportional hazards models using Visit 2 as  
137 the starting point. Analyses were adjusted for sex, race, and age at baseline (Visit 2). For time-to-  
138 event outcomes baseline FEV1 percentage of predicted was included as a covariate. Since the  
139 sample sizes of our vaping/smoking groups were small, these association analyses were  
140 performed in all available COPDGene study subjects without stratifying by vaping or smoking  
141 exposure. The FDR was controlled at 10% using the Benjamini-Hochberg method.

142

#### 143 ***Prediction modeling for vaping status and prospective health outcomes***

144 Predictive models using only transcript and protein biomarkers were constructed for  
145 vaping/smoking groups and prospective health outcomes. For categorical and binary outcomes,  
146 linear discriminant analysis (LDA) was used. For change in FEV1 models, elastic net models  
147 were constructed. Cross-validation was used to prevent overfitting and estimate predictive  
148 performance. Model performance was assessed by cross-validation using the Youden index  
149 (sensitivity + specificity - 1), area under the receiver operator characteristic curve (AUROC), and  
150 area under the precision recall curve (AUCPR) for binary outcomes. R2 was used to evaluate the  
151 performance of change in FEV1 models. Additional details are included in the supplementary  
152 materials of the online preprint.

153

## 154 **Results**

### 155 *Baseline characteristics*

156 A visual overview of the study and data flow is included in Supplemental Figures 1 and  
157 2. There were 51 and 77 subjects reporting current vaping only or dual use, respectively, at the  
158 COPDGene second study visit. Differences in baseline characteristics of these groups along with  
159 the current and former cigarette user groups are reported in Table 1. The large majority of  
160 subjects in the vaping group (80%) reported vaping at least once a day. The dual user group  
161 reported lighter vaping on average, with only 42% reporting daily vaping, and their pack-years  
162 exposure to combustible tobacco was similar to the current cigarette user group. FEV1 % of  
163 predicted values were comparable for all groups. Biochemical confirmation of nicotine exposure  
164 via analysis of plasma cotinine levels in 853 subjects demonstrated elevated cotinine levels in the  
165 vaping, dual use, and current cigarette user groups relative to the former cigarette user group  
166 (Figure 1, Wilcoxon rank sum test  $p < 0.005$  for all comparisons). A subset of the former cigarette  
167 user group had elevated levels of nicotine that could be due to use of nicotine replacement  
168 therapy, secondhand exposure to tobacco smoke or e-cigarette aerosols, or unreported smoking  
169 or vaping.

170

### 171 *Blood RNA-seq associations with vaping and dual use*

172 A total of 18,303 genes were tested for differential expression analysis of vapers, dual  
173 users, and current cigarette users, using former cigarette users as the reference group. The top  
174 results from each analysis are shown in Table 2, and complete results are reported in Tables S1-  
175 S3. For vapers, three significant associations were identified at an FDR of 10% (Figure 2). Two

176 of these genes (*LINC02470* and *NPHP1*) were expressed at a higher level in vapers than any of  
177 the other three groups ( $p < 0.05$  for all comparisons, Table S4). The third gene, *GPR15*, was one  
178 of the most well-reported genes upregulated by smoking. This gene was also upregulated in  
179 vapers, but to a lesser extent than in either cigarette users or dual users ( $p < 0.005$  for all  
180 comparisons). Gene set enrichment analysis identified 16 significant MSigDB Hallmark  
181 pathways with the top three processes being related to inflammation, oxidative phosphorylation,  
182 and heme metabolism (Table 3). For all significant gene sets, enrichment was in the direction of  
183 decreased expression in vapers compared to former cigarette users. Since smoking has been  
184 shown to have mixed effects on inflammation, we compared the pattern of gene set enrichment  
185 for the Hallmark Inflammation pathway in vapers, current cigarette users, and dual users, and we  
186 observed that smoking and dual use show elements of activation and repression of this gene set;  
187 the effect of vaping was more clearly downregulation of this pathway (Supplemental Figure 3).

188 For dual users, 90 differentially expressed genes were identified, and 17 of these genes  
189 were significant only in the dual user analysis. All 17 genes were also significantly differentially  
190 expressed when comparing dual users to current cigarette users, suggesting that these genes have  
191 a distinctive response to dual use ( $p < 0.005$  for all comparisons, see Table S5). Gene set  
192 enrichment analysis identified four significant Hallmark pathways related to heme metabolism,  
193 oxidative phosphorylation, E2F signaling, and interferon gamma response (Table 3). Complete  
194 results for the vaping, dual use, and smoking analyses including MSigDB Immunologic  
195 Signature pathways are presented in Supplemental Tables S6-S8.

196

197 ***Proteomic biomarker associations to vaping and dual use***

198 A total of 4,979 SOMAscan aptamers mapping to 4,720 unique proteins were tested for  
199 association to vaping and smoking groups. The top significantly associated proteins are shown in  
200 Table 2 (see Table S9 for complete results), and violin plots for selected top protein biomarkers  
201 associated with vaping or dual use are shown in Figure 3. Three protein biomarkers (EDIL3,  
202 DPYL5, and KLK13) were significantly associated with vaping status at a 10% FDR, and  
203 DPYL5 expression was found to be higher in vapers compared to each of the other groups  
204 ( $p < 0.05$  for all comparisons, Table S10). One hundred protein biomarkers were associated with  
205 dual use, with four (CXA8, Keratin 19, CSKP, and PXDC1) being significantly associated only  
206 with dual use. All four of these proteins also showed nominal association ( $p < 0.05$ ) in an analysis  
207 comparing dual users to current cigarette users, indicating a distinct response to dual use (Table  
208 S11).

209

### 210 *Comparison of biomarker associations to vaping, smoking, and dual use*

211 To compare the similarity of the transcriptomic and proteomic responses to each exposure, we  
212 constructed pairwise plots of the effect sizes of all significantly associated biomarkers (Figure 4).  
213 There was a strong positive correlation between the biomarker responses to smoking and dual  
214 use (Pearson's  $r = 0.76$  and  $0.88$  for RNA and protein, respectively), whereas the vaping  
215 biomarker profile had low correlation to the profiles for both dual use and smoking ( $r$  between  
216  $0.23$  and  $0.44$ ). Certain biomarkers (LINC02470 and DPYL5 protein) had particularly strong and  
217 unique associations with vaping. When we compared effect sizes between RNA and proteomic  
218 biomarkers associated with vaping and smoking, the correlation was low ( $r = 0.11$ ) as might be  
219 expected given various potential sources of origin for circulating blood proteins.

220

### 221 *Classification accuracy for vaping/smoking behavior using biomarker panels*

222 To determine how well RNA and protein biomarkers could classify subjects according to  
223 their vaping/smoking behavior, we used a nested cross-validation approach to provide an  
224 unbiased estimate of the classification performance achievable by multi-class prediction models  
225 using linear discriminant analysis (LDA). The performance of this model is shown in Table 4,  
226 where for each group the task was to distinguish that group from all other groups combined. The  
227 model achieved good discrimination for current cigarette users (Youden index (YI) = 0.81) and  
228 former cigarette users (YI = 0.80) and had statistically significant but less accurate performance  
229 for vapers (YI = 0.53) and dual users (YI = 0.55). More detailed metrics for each pairwise  
230 contrast (Table S12) demonstrates that the models do better in discriminating vapers from  
231 current cigarette users than former cigarette users (YI = 0.73 and 0.50, respectively), whereas for  
232 dual users, model discrimination was better for former cigarette users (YI = 0.82) than current  
233 cigarette users (YI = 0.34), providing further evidence of the similarity between dual use and  
234 current smoking biomarker profiles.

235

### 236 *Vaping and dual use biomarkers and longitudinal outcomes*

237 To determine whether biomarkers of vaping or dual use were associated with prospective  
238 health-related outcomes, we tested the 92 RNA transcripts and 101 protein biomarkers associated  
239 with vaping and/or dual use for association to multiple health outcomes in all COPDGene  
240 subjects. Twenty-one transcripts and 88 protein biomarkers were associated with one or more of  
241 the studied outcomes at a 10% FDR level. Of the vaping-associated biomarkers, two (KLK13

242 and DPYL5) were associated with loss of FEV1, and KLK13 was also associated with mortality.  
243 Boxplots for the top four vaping or dual use proteins associated with all-cause mortality are  
244 shown in Figure 5, and all significant biomarker associations are shown in Tables S13-S16.

245 We then determined whether the effect of vaping or dual use on each protein biomarker  
246 was consistent with higher or lower risk for each adverse health outcome, and we observed that  
247 the direction of the exposure effect was overwhelmingly towards increased risk for adverse  
248 health events (Figure 6). Out of 246 total significant associations to health outcomes, 224 (91%)  
249 showed concordance between the effect of vaping or dual use and the direction of association to  
250 increased risk. Both of the vaping-associated biomarkers (KLK13 and DPYL5) showed  
251 concordant effects for higher health risk.

252 To estimate the accuracy of multi-marker panels of vaping and dual use biomarkers for  
253 predicting prospective health outcomes, we constructed predictive models for FEV1 decline, all-  
254 cause mortality, COPD exacerbations, and incident CVD using only the vaping or dual use-  
255 associated RNA and protein biomarkers. Models using the seven vaping-associated biomarkers  
256 alone gave non-informative predictions, but models using the 190 dual use-associated  
257 biomarkers gave informative predictions with moderate accuracy for FEV1 decline, all-cause  
258 mortality and respiratory exacerbations (Table 5).

259

### 260 ***Replication of previously reported vaping biomarker associations***

261 A recently published review of vaping biomarkers listed 14 inflammatory and matrix  
262 degradation protein biomarkers that had been previously associated with vaping[19]. We  
263 examined the results from these 14 biomarkers at the RNA and protein level for association to



264 vaping or dual use, and we observed associations at nominal significance ( $p < 0.05$ ) for four  
265 biomarkers (*IL1B*, *ICAM1* [both RNA and protein], *IL-6*, and *MMP9*, see Table S17).

266

## 267 **Discussion**

268 Identifying validated biomarkers of vaping and dual use is an important tool both for  
269 guiding ENDS users as to the risks of these devices and effective regulation of ENDS. This study  
270 of established adult cigarette users identified significant associations of six and 190 blood  
271 molecular markers with vaping and dual use, respectively. Because of the comprehensive nature  
272 of the ‘omics measurements, we were able to compare overall molecular profiles of vaping, dual  
273 use, and smoking. These analyses found that the vaping profile was substantially different from  
274 current smoking, whereas dual use and smoking were similar but not identical. Biomarkers  
275 associated with vaping and dual use were also associated with multiple cardiopulmonary health  
276 outcomes, and reasonably predictive accuracy for some of these outcomes could be achieved for  
277 models using dual use biomarkers.

278 A previous metabolomic biomarker study by Goniewicz *et al.* demonstrated that vaping  
279 is associated with metabolomic changes, albeit at generally lower levels compared to current  
280 cigarette users or dual users[20]. A recent study of vapers versus non-cigarette users identified  
281 numerous changes in plasma biomarkers associated with inflammation, oxidative stress, and  
282 extracellular matrix degradation[19]. A recent meta-analysis of biomarkers of ENDS versus  
283 cigarettes reported a more favorable biomarker profile of ENDS use, though the last author of the  
284 study has been reported to have ties to the tobacco industry[21,22]. Another systematic review  
285 also reported reduced levels of some biomarkers in ENDS users relative to current cigarette

286 users, but this is not consistent for all biomarkers ([Hiler et al., 2021](#)). By examining the  
287 correlation in biomarker profiles for vaping, dual use, and smoking, we observed that the vaping  
288 profile is largely distinct from both the dual use and smoking profile which are in turn highly  
289 correlated to each other. We did however observe multiple examples of shared RNA and protein  
290 biomarkers between smoking, vaping, and dual use, such as *GPR15*, a regulator of inflammation  
291 and T-cell trafficking. We also provided independent validation for previously reported vaping  
292 or dual use associations with *IL1B*, *ICAM1*, *IL-6*, and *MMP9*, all of which are known to  
293 influence inflammation (*IL-1B* can induce *MMP-9* expression and activity).

294 Both vaping and dual use are associated with diverse effects on biological pathways  
295 related to aspects of inflammation, oxidative phosphorylation, and coagulation-related pathways.  
296 Previous studies have also shown that long non-coding RNAs (lncRNAs) are associated with  
297 vaping[23,24], and in our work we identified *LINC02470* as a novel vaping biomarker.  
298 *LINC02470* has previously been reported to modulate Wnt-beta catenin signaling via exosomal  
299 secretion from bladder cancer cells[25]. Because Tang *et al.* previously demonstrated bladder  
300 urothelial hyperplasia in mice exposed daily to e-cigarette aerosols, the finding of *LINC02470* in  
301 the circulation of human ENDS users is highly concerning. We also identified *DPYL5* as being  
302 uniquely upregulated in vaping subjects. *DPYL5* is primarily expressed in brain tissue and glial  
303 cells, though it is also expressed at detectable levels in the gastrointestinal (GI) tract. *DPYL5* is  
304 potentially an important vaping biomarker, because it was also predictive of future loss of lung  
305 function. To our knowledge, this is the first report of *DPYL5* as a specific and clinically relevant  
306 biomarker of vaping, a finding that requires further independent validation.

307 Many of the biomarkers altered by vaping and dual use are also associated with risk of  
308 adverse health events such as loss of lung function, respiratory exacerbations, and mortality. For

309 the overwhelming majority of biomarkers, the direction of effect of vaping and dual use was  
310 consistent with increased health risk. This extends numerous prior observations linking vaping to  
311 a variety of pulmonary symptoms and alterations of cardiovascular physiology[26], providing an  
312 important link to longer-term health outcomes and suggesting that some of these biomarkers may  
313 be useful in assessing health risks of specific vaping devices and e-liquid formulations. For dual  
314 use, a multi-marker panel of associated biomarkers achieved modest predictive accuracy for  
315 some important outcomes. For vapers, the biomarker profile was more subtle, and with our  
316 current sample size we did not identify a sufficient number of biomarkers to enable accurate  
317 multi-marker prediction of health outcomes.

318 The strengths of this study are the high-throughput approach to biomarker discovery, the  
319 characterization of associations to prospective health events, and the use of machine learning to  
320 assess the predictive performance of multimarker panels. Limitations include a modest sample  
321 size of vapers and dual users and the lack of independent replication due to lack of available  
322 cohorts with similar biomarker data and exposure characterization. Information regarding  
323 specific vaping devices and fluids was limited and reflects the challenges posed by the rapid  
324 evolution of vaping devices over the study period. Our findings cannot be assumed to generalize  
325 to newer-generation vaping devices which will require dedicated study, and our findings in  
326 adults do not necessarily apply to other important groups such as adolescents.

327 In conclusion, this study identified over one-hundred transcriptomic and proteomic  
328 biomarkers associated with vaping and dual use, and many of these biomarkers are also  
329 associated with prospective cardiopulmonary health outcomes. Prediction of health outcomes  
330 using multimarker panels can provide informative prediction with room for improvement, and  
331 validation in independent cohorts will increase confidence in individual biomarkers and multi-

332 marker models. Larger-scale studies with greater power would be likely to identify additional  
333 biomarkers that could further improve predictive model performance.

334

### 335 **Data availability**

336 Supplemental materials are included in the medRxiv online preprint (doi:  
337 <https://doi.org/10.1101/2022.09.19.22280093>).

### 338 *Underlying data*

339 NCBI dbGAP: [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2)  
340 [bin/study.cgi?study\\_id=phs000179.v6.p2](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2)

341

342

### 343 **Competing interests**

344 EKS and PJC have received grant support from GlaxoSmithKline and Bayer. JY has received  
345 institutional grant support from Bayer and personal fees from Bride Biotherapeutics outside the  
346 submitted work.

347

### 348 **Grant information**

349 This work was supported by NHLBI K08HL141601, K08HL146972, K01HL157613,  
350 R01HL124233, U01 HL089897, R01 HL147326, and U01 HL089856. The COPDGene study

351 (NCT00608764) is also supported by the COPD Foundation through contributions made to an  
352 Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals,  
353 Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.

**Table 1.** Baseline characteristics of the vaping and smoking groups

	<b>Current cigarette users (n = 1,328)</b>	<b>Former cigarette users (n = 2,436)</b>	<b>Vapers (n = 51)</b>	<b>Dual users (n = 77)</b>	<b>P- value</b>
Age	59.6 (9.5)	68.6 (11.9)	64.6 (10.2)	61.6 (9.9)	< 0.001
Sex, % male	50.5%	52.0%	39.2%	48.1%	0.3
% Non-Hispanic Whites	47.1%	82.4%	88.2%	71.4%	< 0.001
BMI	27.2 (8.4)	28.7 (7.6)	29.2 (9.6)	26.9 (7.1)	< 0.001
Smoking pack-years	41.1 (25.8)	38.0 (29.2)	50.1 (26.3)	45.0 (26.3)	< 0.001
FEV <sub>1</sub> (L)	2.2 (1.1)	2.1 (1.2)	2.1 (1.2)	2.1 (1.2)	< 0.001
FEV <sub>1</sub> , % predicted	81.9 (28.0)	82.0 (35.6)	83.2 (32.7)	76.9 (29.7)	0.2
FVC (L)	3.1 (1.4)	3.0 (1.4)	3.1 (1.5)	3.0 (1.5)	0.02
Use of e-cigarettes:					
Less than once a month	NA	NA	0.0%	2.6%	0.3
Less than once a week	NA	NA	0.0%	15.6%	0.003
Some days (1-3 days a week)	NA	NA	4.0%	27.3%	< 0.001
Most days	NA	NA	16.0%	13.0%	0.6
Every day	NA	NA	80.0%	41.6%	< 0.001
Cartridge size:					
0 mg	NA	NA	8.2%	4.0%	0.3
6-8 mg	NA	NA	20.4%	16.0%	0.5
9-12 mg	NA	NA	14.3%	9.3%	0.4
13-16 mg	NA	NA	14.3%	6.7%	0.2
Do not know	NA	NA	22.5%	52.0%	0.001
Other	NA	NA	20.4%	12.0%	0.2
Number of e-cigarettes used (last 24 hours)	NA	NA	10 (16)	3 (10)	< 0.001
Number of cartridges used/week	NA	NA	2 (6)	1 (1)	0.002
E-cigarette brand:					
Blu	NA	NA	4.6%	17.4%	0.04
Henley	NA	NA	2.3%	1.5%	0.7
Joye	NA	NA	0.0%	2.9%	0.3
NJOY	NA	NA	2.3%	8.7%	0.2
V2	NA	NA	2.3%	2.9%	0.8
Other	NA	NA	90.9%	71.0%	0.01
SGRQ Symptom Score	28.7 (40.4)	17.9 (39.0)	15.8 (46.3)	43.5 (48.5)	< 0.001
Respiratory exacerbation	14.4%	17.9%	21.6%	23.4%	0.01
CVD	18.5%	25.8%	15.7%	18.2%	< 0.001
<p>Continuous variables are reported as medians (interquartile ranges). Categorical variables are reported as percentages. Kruskal-Wallis rank sum tests were used for continuous variables. Chi-square tests were used for categorical variables. BMI: Body mass index; CVD: Cardiovascular disease (history of stroke, heart attack, coronary artery disease, coronary artery bypass graft surgery, peripheral artery disease, and/or cardiac angina); Respiratory exacerbation: At least one respiratory exacerbation (acute worsening of respiratory symptoms that required systemic steroids and/or antibiotics) in the previous year; FEV<sub>1</sub>: Forced expiratory volume in 1 second; FEV<sub>1</sub>, % predicted: Observed FEV<sub>1</sub> / Predicted FEV<sub>1</sub> based Hankinson reference equation; FVC: Forced vital capacity; SGRQ: St. George's respiratory questionnaire score. % LAA-950: Percentage of CT low attenuation less than -950 HU at end-inspiration using Thirona software; % Segmental airway wall thickness: Percentage of the wall relative to the total bronchial area for the segmental airways. NA = Not applicable.</p>					

**Table 2.** Top 5 differentially associated genes and proteins for vapers, dual users, and current cigarette users.

	Genes				Proteins			
	Gene	Ensembl gene ID	Log fold change	q-value	Protein	Uniprot ID	Mean difference	q-value
<b>Vaping</b>	<i>GPR15</i>	ENSG00000154165	0.90	<0.001	EDIL3	O43854	0.52	0.03
	<i>NPHP1*</i>	ENSG00000144061	0.79	0.05	DPYL5*	Q9BPU6	0.62	0.03
	<i>LINC02470*</i>	ENSG00000225231	1.37	0.07	Kallikrein 13	Q9UKR3	0.54	0.09
<b>Dual use</b>	<i>SEMA6B</i>	ENSG00000167680	2.10	<0.001	Placental alkaline phosphatase	P05187	1.12	<0.001
	<i>MIR124-1HG</i>	ENSG00000253230	2.32	<0.001	PPBN	P10696	0.92	<0.001
	<i>GPR15</i>	ENSG00000154165	1.71	<0.001	LPLC1	Q8TDL5	0.88	<0.001
	<i>LRRN3</i>	ENSG00000173114	1.59	<0.001	PSP-94	P08118	0.88	<0.001
	<i>CTTNBP2</i>	ENSG00000077063	1.52	<0.001	sICAM-5	Q9UMF0	0.84	<0.001
<b>Current cigarette use</b>	<i>GPR15</i>	ENSG00000154165	1.34	<0.001	Placental alkaline phosphatase	P05187	1.00	<0.001
	<i>MIR124-1HG</i>	ENSG00000253230	1.79	<0.001	PPBN	P10696	0.89	<0.001
	<i>SEMA6B</i>	ENSG00000167680	1.51	<0.001	PSP-94	P08118	0.77	<0.001
	<i>LRRN3</i>	ENSG00000173114	1.21	<0.001	LPLC1	Q8TDL5	0.72	<0.001
	<i>P2RY6</i>	ENSG00000171631	0.88	<0.001	PIGR	P01833	0.73	<0.001

Differential gene expression and protein association analyses was performed for each vaping/smoking group using the former cigarette user group as reference and adjusting for age, sex, race and batch effects. Up to 5 significant biomarkers are shown. “Uniquely” significant biomarkers (i.e. biomarkers significant at 10% FDR for one contrast but not for any of the other contrasts) are indicated with \*. Effect sizes are reported as log fold change for the RNA-seq analysis and mean difference in normalized RFU (relative fluorescence units) for the proteomics analysis. Q-values calculated using the Benjamini-Hochberg procedure implemented in the p.adjust function in R.

**Table 3.** Top 5 significant (adjusted P-values < 0.1) MSigDB Hallmark pathways from differential gene expression analyses for the vaping and smoking groups.

	<b>MSigDB Hallmark pathway</b>	<b>Pathway ID</b>	<b>Number of genes</b>	<b>NES</b>	<b>Adjusted P-value</b>
<b>Vaping</b>	Inflammatory Response	M5932	163	-4.10	6.3x10 <sup>-10</sup>
	Oxidative Phosphorylation	M5936	200	-4.01	2.8x10 <sup>-9</sup>
	Heme Metabolism	M5945	195	-3.82	2.7x10 <sup>-8</sup>
	TNF- $\alpha$ Signaling via NF-kB	M5890	179	-3.85	3.7x10 <sup>-8</sup>
	Complement	M5921	171	-3.50	4.0x10 <sup>-7</sup>
<b>Dual Use</b>	Heme Metabolism	M5945	195	-5.53	3.9x10 <sup>-17</sup>
	Oxidative Phosphorylation	M5936	200	-3.70	1.7x10 <sup>-7</sup>
	E2F Targets	M5925	199	-3.69	2.0x10 <sup>-7</sup>
	Interferon gamma response	M5913	194	-2.90	1.4x10 <sup>-4</sup>
<b>Current cigarette use</b>	Heme Metabolism	M5945	195	-8.68	1.2x10 <sup>-48</sup>
	MYC Targets V1	M5926	200	3.33	6.1x10 <sup>-6</sup>
	Estrogen Response Late	M5907	145	-2.89	2.2x10 <sup>-4</sup>
	Xenobiotic Metabolism	M5934	151	-2.86	3.2x10 <sup>-4</sup>
	Epithelial mesenchymal transition	M5930	129	-2.86	3.8x10 <sup>-4</sup>

Gene set enrichment analysis (GSEA) was performed using the results from the differential expression analysis comparing vapers, dual users, or current cigarette users to former cigarette users. Genes were ranked for enrichment analysis by log fold change. The top 5 results from the MSigDB Hallmarks gene sets are shown ordered by p-value. The “number of genes” column is the number of genes associated with the GSEA pathway that could be mapped to the differential expression results. Abbreviations: NES = normalized enrichment score. UV= ultraviolet light.



**Table 4.** Multi-class prediction of vaping and smoking groups using multi-omic biomarkers

	Integrated RNA-seq and proteomic data			
	Current cigarette users	Former cigarette users	Vapers	Dual users
AUROC	0.94	0.94	0.71	0.71
AUPRC	0.85	0.97	0.06	0.04
Youden index	0.81	0.80	0.53	0.55
Linear discrimination analysis models were used to classify vaping and smoking groups. For each group, LDA models are constructed to distinguish that group from the other three using 10-fold nested cross validation (CV) to estimate performance. Abbreviations: AUROC = Area under the receiving operating characteristic curve; AUPRC = Area under the precision-recall curve. The Youden Index (YI) metric was used to summarize the model performance at the optimal cutoff on the area under the receiver operating curve.				

**Table 5.** Performance metrics of prediction models for prospective health outcomes.

Biomarker Panel	Outcome	Sample size (events)	AUROC	AUPR	Youden Index	R2
Dual Use Biomarkers	Δ FEV1 (ml/yr)	642	NA	NA	NA	0.08
	Δ FEV1 (% of baseline)	642	NA	NA	NA	0.17
	Overall mortality	2388 (246)	0.68	0.38	0.36	NA
	Exacerbation ≥ 1	2231 (811)	0.63	0.51	0.25	NA
	Incident CVD	1700 (183)	0.68	0.34	0.36	NA
<p>Prediction models for the indicated outcomes were constructed using elastic net for change in FEV1 models and linear discriminant analysis for binary outcomes. <math>\Delta</math> FEV1 (ml/yr) = (FEV1 at visit 3 - FEV1 at visit 2) / years between visits. <math>\Delta</math> FEV1 (% of baseline) = <math>\Delta</math> FEV1 (ml/yr) / FEV1 at visit 2. Exacerbation = 1 if subjects reported one or more exacerbation over the follow-up period after visit 2 and 0 otherwise. Incident CVD = 1 if subject reported new diagnosis of CVD after visit 2, and subjects with existing CVD at visit 2 were excluded. AUROC = area under the receiver operator characteristic. AUPR = area under the precision-recall curve. R2 = r-squared.</p>						

## **Figure Legends:**

**Figure 1. Plasma cotinine levels by vaping/smoking group.** In a subset of subjects, plasma metabolomics data was measured using the Metabolon Global Metabolomics Platform. Violin plots of log-transformed cotinine raw area counts are shown. Cotinine levels are significantly higher in all three groups relative to FS (Wilcoxon rank sum  $p < 0.005$  for all three comparisons). FS = former cigarette users. CS = current cigarette users.

**Figure 2. Significantly associated vaping RNA biomarkers.** Three RNA biomarkers were significantly associated at 10% FDR in the analysis comparing vapers to former cigarette users. *NPHP1* and *LINC02470* were significantly associated in the vaping but not the smoking or dual use comparison to former cigarette users. *GPR15* is significantly elevated in all three groups relative to former cigarette users, but its expression is relatively lower in vapers relative to dual users and current cigarette users ( $p < 0.005$  for all comparisons).

**Figure 3. Top protein biomarkers significantly associated with vaping or dual use.** The distribution of the top significantly associated protein biomarkers in the analysis of vapers or dual users versus former cigarette users. *DPYL5* is significantly elevated in vapers relative to all other vaping/smoking groups ( $p < 0.005$ ). *KLK13* is significantly associated with vapers, dual users, and current cigarette users when compared to former cigarette users. *s-ICAM5* and Secretoglobin family member 3A member 1 were significantly associated with dual users and current cigarette users but not vapers when compared to former cigarette users.

**Figure 4. Correlation of biomarker responses between vapers, dual users, and current cigarette users.** Comparison of the biomarker association profiles demonstrates that while the dual user and current cigarette user profiles are very similar, the vaping biomarker profile is more distinct. For the RNA and protein biomarker analysis of vaping/smoking groups versus former cigarette users, the effect sizes for each pair of comparisons were plotted and the Pearson correlation of effect sizes was calculated. In each pairwise comparison, only biomarkers significant in at least one of analyses were analyzed. In row A, vaping-associated RNA biomarker effects are compared to current cigarette user effects (left), dual user effects (middle), and then dual user and current cigarette user effects are compared (right). In row B, the corresponding protein biomarker effects are compared.

**Figure 5. Top protein vaping and dual use biomarkers significantly associated with overall mortality.** The dual use-associated proteins Growth hormone receptor, MIC-1, and HE4 were significantly associated with overall mortality. KLK-13 was the only vaping associated biomarker that was also associated mortality. All associations were significant at a false discovery rate of 10%.

**Figure 6. Concordance analysis of biomarker associations to vaping/dual use and adverse health outcomes.** For protein biomarkers that were significantly associated with at least one health outcome and vaping (n=2) or dual use (n=86), we plotted the effect of the exposure (vaping or dual use) against the effect with respect to the health outcome. Since some biomarkers were significantly associated with multiple health outcomes, the total number of analyzed

associations was 246. The top panel shows the relationship between exposure effect and change FEV1 (ml/yr) where each of the 107 associations was concordant for loss of FEV1. Change in FEV1 is calculated as visit 3 value - visit 2 value, meaning negative values indicate loss of lung function. The bottom panel shows the relationship between exposure effect and hazard ratio for all cause mortality, respiratory mortality, exacerbations, or incident cardiovascular disease. 117 of 139 associations were concordant for higher health risk. Exposure effect is the beta coefficient from the dual use versus former cigarette users analysis, except for DPYL5 and KLK13 which is from the vapers versus former cigarette users analysis.

## **References**

- 1\_\_\_ Gentzke AS, Wang TW, Jamal A, *et al.* Tobacco Product Use Among Middle and High School Students - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:1881–8.
- 2\_\_\_ Mayer M, Reyes-Guzman C, Grana R, *et al.* Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. *JAMA Netw Open* 2020;**3**:e2020694.
- 3\_\_\_ Li D, Sundar IK, McIntosh S, *et al.* Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. *Tobacco Control*. 2019;:tobaccocontrol – 2018. doi:10.1136/tobaccocontrol-2018-054694
- 4\_\_\_ Yao T, Max W, Sung H-Y, *et al.* Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. *PLoS One* 2017;**12**:e0187399.
- 5\_\_\_ St Helen G, Eaton DL. Public Health Consequences of e-Cigarette Use. *JAMA Intern Med* 2018;**178**:984–6.
- 6\_\_\_ Smith ML, Gotway MB, Crotty Alexander LE, *et al.* Vaping-related lung injury. *Virchows Arch* 2021;**478**:81–8.
- 7\_\_\_ Cherian SV, Kumar A, Estrada-Y-Martin RM. E-Cigarette or Vaping Product-Associated Lung Injury: A Review. *Am J Med* 2020;**133**:657–63.
- 8\_\_\_ Hammond D, Reid JL, Rynard VL, *et al.* Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;**365**:l2219.
- 9\_\_\_ Miech R, Johnston L, O’Malley PM, *et al.* Trends in Adolescent Vaping, 2017–2019. *N Engl J Med* 2019;**381**:1490–1.
- 10\_\_\_ Miech R, Johnston L, O’Malley PM, *et al.* Adolescent vaping and nicotine use in 2017–2018 - U.s. national estimates. *N Engl J Med* 2019;**380**:192–3.
- 11\_\_\_ Aronson JK. Research priorities in biomarkers and surrogate end-points. *Br J Clin Pharmacol* 2012;**73**:900–7.
- 12\_\_\_ FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and Other Tools) Resource*. Food and Drug Administration (US) 2016.
- 13\_\_\_ Regan EA, Hokanson JE, Murphy JR, *et al.* Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;**7**:32–43.

- 14 Gold L, Ayers D, Bertino J, *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* 2010;**5**:e15004.
- 15 Gillenwater LA, Kechris KJ, Pratte KA, *et al.* Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema. *Metabolites* 2021;**11**. doi:10.3390/metabo11030161
- 16 Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**:e47.
- 17 Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc* 1995;**57**:289–300.
- 18 Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N. Artyomov, Alexey Sergushichev. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. biorxiv. 2021. doi:10.1101/060012
- 19 Singh KP, Lawyer G, Muthumalage T, *et al.* Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. *ERJ Open Res* 2019;**5**. doi:10.1183/23120541.00182-2019
- 20 Goniewicz ML, Smith DM, Edwards KC, *et al.* Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. *JAMA Netw Open* 2018;**1**:e185937.
- 21 Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. *Toxicology Reports*. 2021;**8**:282–94. doi:10.1016/j.toxrep.2021.01.014
- 22 Neil Sherwood. TobaccoTactics. 2020.<https://tobaccotactics.org/wiki/neil-sherwood/> (accessed 26 Jun 2022).
- 23 Tommasi S, Caliri AW, Caceres A, *et al.* Deregulation of Biologically Significant Genes and Associated Molecular Pathways in the Oral Epithelium of Electronic Cigarette Users. *Int J Mol Sci* 2019;**20**. doi:10.3390/ijms20030738
- 24 Kaur G, Singh K, Maremanda KP, *et al.* Differential plasma exosomal long non-coding RNAs expression profiles and their emerging role in E-cigarette users, cigarette, waterpipe, and dual smokers. *PLoS One* 2020;**15**:e0243065.
- 25 Huang C-S, Ho J-Y, Chiang J-H, *et al.* Exosome-Derived LINC00960 and LINC02470 Promote the Epithelial-Mesenchymal Transition and Aggressiveness of Bladder Cancer Cells. *Cells* 2020;**9**. doi:10.3390/cells9061419
- 26 Bozier J, Chivers EK, Chapman DG, *et al.* The Evolving Landscape of e-Cigarettes: A Systematic Review of Recent Evidence. *Chest* 2020;**157**:1362–90.